Harmony Biosciences saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 67 to 80.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the best-performing stocks often have an RS Rating north of 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Harmony Biosciences is working on a consolidation with a 41.61 buy point. See if it can break out in heavy trading.
Harmony Biosciences showed 6% EPS growth last quarter. Sales rose 16%.
Harmony Biosciences earns the No. 5 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
